Endocrine therapy of human breast cancer cells: The role of secreted polypeptide growth factors

N. Brunner, G. Zugmaier, M. Bano, B. W. Ennis, R. Clarke, K. J. Cullen, F. G. Kern, R. B. Dickson, Marc E Lippman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Endocrine therapy is an important modality in the treatment of breast cancer. However, the precise molecular mechanisms underlying the growth inhibitory effect of endocrine therapy are unknown. Recently, it has been shown that breast cancer cells express and secrete polypeptide growth factors that can regulate the growth of the cells through autocrine and/or paracrine pathways. These growth factors are thought to be involved in the response to endocrine therapy. Three different mechanisms have been suggested: (1) stimulation of growth inhibitory peptides; (2) repression of mitogenic peptides; and (3) stimulation of mitogenic growth factors in cells overexpressing the corresponding receptor. This article reviews the scientific evidence on which these hypotheses are based.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalCancer Cells
Volume1
Issue number3
StatePublished - Dec 1 1989
Externally publishedYes

Fingerprint

Intercellular Signaling Peptides and Proteins
Breast Neoplasms
Peptides
Growth
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Brunner, N., Zugmaier, G., Bano, M., Ennis, B. W., Clarke, R., Cullen, K. J., ... Lippman, M. E. (1989). Endocrine therapy of human breast cancer cells: The role of secreted polypeptide growth factors. Cancer Cells, 1(3), 81-86.

Endocrine therapy of human breast cancer cells : The role of secreted polypeptide growth factors. / Brunner, N.; Zugmaier, G.; Bano, M.; Ennis, B. W.; Clarke, R.; Cullen, K. J.; Kern, F. G.; Dickson, R. B.; Lippman, Marc E.

In: Cancer Cells, Vol. 1, No. 3, 01.12.1989, p. 81-86.

Research output: Contribution to journalArticle

Brunner, N, Zugmaier, G, Bano, M, Ennis, BW, Clarke, R, Cullen, KJ, Kern, FG, Dickson, RB & Lippman, ME 1989, 'Endocrine therapy of human breast cancer cells: The role of secreted polypeptide growth factors', Cancer Cells, vol. 1, no. 3, pp. 81-86.
Brunner N, Zugmaier G, Bano M, Ennis BW, Clarke R, Cullen KJ et al. Endocrine therapy of human breast cancer cells: The role of secreted polypeptide growth factors. Cancer Cells. 1989 Dec 1;1(3):81-86.
Brunner, N. ; Zugmaier, G. ; Bano, M. ; Ennis, B. W. ; Clarke, R. ; Cullen, K. J. ; Kern, F. G. ; Dickson, R. B. ; Lippman, Marc E. / Endocrine therapy of human breast cancer cells : The role of secreted polypeptide growth factors. In: Cancer Cells. 1989 ; Vol. 1, No. 3. pp. 81-86.
@article{fdd7ada4e41049e2901b9c3647e8a2ab,
title = "Endocrine therapy of human breast cancer cells: The role of secreted polypeptide growth factors",
abstract = "Endocrine therapy is an important modality in the treatment of breast cancer. However, the precise molecular mechanisms underlying the growth inhibitory effect of endocrine therapy are unknown. Recently, it has been shown that breast cancer cells express and secrete polypeptide growth factors that can regulate the growth of the cells through autocrine and/or paracrine pathways. These growth factors are thought to be involved in the response to endocrine therapy. Three different mechanisms have been suggested: (1) stimulation of growth inhibitory peptides; (2) repression of mitogenic peptides; and (3) stimulation of mitogenic growth factors in cells overexpressing the corresponding receptor. This article reviews the scientific evidence on which these hypotheses are based.",
author = "N. Brunner and G. Zugmaier and M. Bano and Ennis, {B. W.} and R. Clarke and Cullen, {K. J.} and Kern, {F. G.} and Dickson, {R. B.} and Lippman, {Marc E}",
year = "1989",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "81--86",
journal = "Cancer Cells",
issn = "1042-2196",
number = "3",

}

TY - JOUR

T1 - Endocrine therapy of human breast cancer cells

T2 - The role of secreted polypeptide growth factors

AU - Brunner, N.

AU - Zugmaier, G.

AU - Bano, M.

AU - Ennis, B. W.

AU - Clarke, R.

AU - Cullen, K. J.

AU - Kern, F. G.

AU - Dickson, R. B.

AU - Lippman, Marc E

PY - 1989/12/1

Y1 - 1989/12/1

N2 - Endocrine therapy is an important modality in the treatment of breast cancer. However, the precise molecular mechanisms underlying the growth inhibitory effect of endocrine therapy are unknown. Recently, it has been shown that breast cancer cells express and secrete polypeptide growth factors that can regulate the growth of the cells through autocrine and/or paracrine pathways. These growth factors are thought to be involved in the response to endocrine therapy. Three different mechanisms have been suggested: (1) stimulation of growth inhibitory peptides; (2) repression of mitogenic peptides; and (3) stimulation of mitogenic growth factors in cells overexpressing the corresponding receptor. This article reviews the scientific evidence on which these hypotheses are based.

AB - Endocrine therapy is an important modality in the treatment of breast cancer. However, the precise molecular mechanisms underlying the growth inhibitory effect of endocrine therapy are unknown. Recently, it has been shown that breast cancer cells express and secrete polypeptide growth factors that can regulate the growth of the cells through autocrine and/or paracrine pathways. These growth factors are thought to be involved in the response to endocrine therapy. Three different mechanisms have been suggested: (1) stimulation of growth inhibitory peptides; (2) repression of mitogenic peptides; and (3) stimulation of mitogenic growth factors in cells overexpressing the corresponding receptor. This article reviews the scientific evidence on which these hypotheses are based.

UR - http://www.scopus.com/inward/record.url?scp=0024958463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024958463&partnerID=8YFLogxK

M3 - Article

C2 - 2701652

AN - SCOPUS:0024958463

VL - 1

SP - 81

EP - 86

JO - Cancer Cells

JF - Cancer Cells

SN - 1042-2196

IS - 3

ER -